Anavex Life Sciences Corp DEFA14A, filed Sep 1, 2026
Anavex Life Sciences Corp. (AVXL)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
| Filed by the Registrant ☒ |
Filed by a Party other than the Registrant ☐
| Check the appropriate box: | ||
| ☐ | Preliminary Proxy Statement | |
| ☐ | Confidential, For Use of the Commission Only (As permitted by Rule 14a-6(e)(2)) | |
| ☐ | Definitive Proxy Statement | |
| ☒ | Definitive Additional Materials | |
| ☐ | Soliciting Material under § 240.14a-12 | |
ANAVEX LIFE SCIENCES CORP.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required | |
| ☐ | Fee paid previously with preliminary materials | |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
On September 1, 2026, representatives of Anavex Life Sciences Corp. (“Anavex” or the “Company”) held a meeting with representatives of Institutional Shareholder Services Inc. (“ISS”) regarding the Company’s 2026 Annual Meeting of Stockholders scheduled for September 24, 2026. A copy of the presentation provided by the Company to ISS is attached hereto.
